{
  "data": {
    "indicator": {
      "slug": "t-cell-engager-market-size-for-multiple-myeloma",
      "name": "T-cell engager market size for multiple myeloma",
      "definition": "Total market value of T-cell engagers for multiple myeloma.",
      "unit": "USD",
      "scale": "billion",
      "default_unit": "USD",
      "default_scale": "billion"
    },
    "scale": "billion",
    "unit": "USD",
    "region": {
      "code": "US",
      "name": "United States",
      "type": "country"
    },
    "points": [
      {
        "period_start": "2032-01-01",
        "period_label": "2032",
        "value": 10,
        "scale": "billion",
        "unit": "USD",
        "value_type": "forecast",
        "statistic_id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGGE",
        "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGGE",
        "source_org": "GSK",
        "source": {
          "org": "GSK",
          "org_short_name": "GSK",
          "document_title": "GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences",
          "document_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/",
          "locator": "Deal aligned to GSK’s portfolio in blood cancer and approach of acquiring differentiated assets with validated targets",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "US"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}